Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
Hirotsugu YamadaAtsushi TanakaKenya KusunoseRie AmanoMunehide MatsuhisaHiroyuki DaidaMasaaki ItoHiroyuki TsutsuiMamoru NanasatoHaruo KamiyaYasuko K BandoMasato OdawaraHisako YoshidaToyoaki MuroharaMasataka SataKoichi Nodenull nullPublished in: Cardiovascular diabetology (2017)
Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e') independent of other clinical variables such as blood pressure and glycemic control. Trial registration UMIN000004490 (University Hospital Medical Information Network Clinical Trials). https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005356 ; registered November 1, 2010.
Keyphrases
- left ventricular
- blood pressure
- clinical trial
- left atrial
- hypertrophic cardiomyopathy
- mitral valve
- cardiac resynchronization therapy
- heart failure
- acute myocardial infarction
- aortic stenosis
- ejection fraction
- chronic obstructive pulmonary disease
- type diabetes
- healthcare
- minimally invasive
- oxidative stress
- randomized controlled trial
- heart rate
- phase iii
- health information
- social media
- coronary artery disease
- metabolic syndrome
- atrial fibrillation
- open label
- phase ii
- extracorporeal membrane oxygenation